Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Sensitivity of AML Cells with FLT3- to PKC412 In Vitro].

Zhongguo shi yan xue ye xue za zhi - 1 Oct 2017

Wang Yin-Ying, Liu Cong-Yan, Zhang Wei, He Jing-Juan, Su Li, Sun Wan-Ling

Abstract excerpt

OBJECTIVE: To explore the clinical value of PKC412 (midostaurin) in treatment of AML patients with FLT3-. METHODS: The bone marrow or peripheral blood were collected and heparinized from 21 newly diagnosed FLT3- AML patients, then the mononuclear cells from bone marrow or peripheral blood were isolated by density-gradient method. The sensitivity of leukemia cells to PKC412 of 8 concentration in vitro was detected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to FLT3 gene
Share to fms-Like Tyrosine Kinase 3
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Staurosporine

Source

Identifiers

PMID: 29070106
DOI: 10.7534/j.issn.1009-2137.2017.05.012

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Sensitivity of AML Cells with FLT3- to PKC412 In Vitro].PMID 29070106Read ↗

Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.Semantic proximity Read ↗

Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.Semantic proximity Read ↗

[Research Progress on Treating Acute Myeloid Leukemia by Midostaurin].Semantic proximity Read ↗

Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.Semantic proximity Read ↗

Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.Semantic proximity Read ↗

Synergistic effect of all‑trans retinoic acid in combination with protein kinase C 412 in FMS-like tyrosine kinase 3-mutated acute myeloid leukemia cells.Semantic proximity Read ↗

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.Semantic proximity Read ↗

Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.Semantic proximity Read ↗

The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations.Semantic proximity Read ↗

Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.Semantic proximity Read ↗

Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.Semantic proximity Read ↗

PKC-β/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.